Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Shipping: The Corridors of Trade and the Coming of Another Period - 2Step by step instructions to Guarantee Your Lab Precious stone is Morally Obtained
- 3Holiday season sees uptick in norovirus cases, according to CDC
- 4'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- 5New subclade K flu strain raises concerns: What families should know
- Must-See Attractions in France
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
- Here's what can happen if you drive under the influence of pot
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- The Development of Shipping: Controlling Towards a More Associated Future
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
